Immutep (IMMP)

• Market cap: $293M
• 1 day: -2.45%
• 5 days: -2.93%
• 1 month: 11.17%
• 3 months: 10.56%
• 6 months: 20.61%
• Year to date: -9.95%
• 1 year: 3.65%
• 5 years: 14.37%
• 10 years: -52.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Employees: 51